Apomorphine - RP Scherer

Drug Profile

Apomorphine - RP Scherer

Latest Information Update: 14 Aug 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RP Scherer
  • Developer Orion; RP Scherer
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 20 Oct 2003 Orion has terminated research of apomorphine and seeks to outlicense the agent
  • 15 Mar 2002 Phase-III clinical trials in Parkinson's disease in Europe (PO)
  • 15 Mar 2002 The fast-dissolving tablet formulation of apomorphine has received orphan drug status in Europe for the treatment of off-periods in patients with Parkinson's disease who are not responding to other oral medications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top